Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Moleculin Biotech, Inc. (NASDAQ:MBRX) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $4.58 and traded as low as $3.85. Moleculin Biotech shares last traded at $4.31, with a volume of 158,257 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target (up from $4.00) on shares of Moleculin Biotech in a report on Thursday, December 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. Finally, Roth Mkm reiterated a “buy” rating on shares of Moleculin Biotech in a research note on Monday, December 15th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $61.00.

Moleculin Biotech Price Performance

The stock’s fifty day simple moving average is $4.58 and its two-hundred day simple moving average is $9.70. The company has a market capitalization of $8.79 million, a price-to-earnings ratio of -0.13 and a beta of 1.65.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.07. On average, sell-side analysts predict that Moleculin Biotech, Inc. will post -7.98 EPS for the current year.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.